Superworth

Pfizer price to free cash flow PFE

Market value divided by free cash flow over the last twelve months, since 2010.

Today, Oct 23, 2026
15.6×
10-year median
15.0×
Against its 10-year history
58th
percentile: 0 is its lowest day, 100 its highest
10-year range
8.2× to 34.7×
Peer median
22.3×

Pfizer's price to free cash flow is 15.6× as of Oct 23, 2026.

That is above its ten-year median of 15.0×, close to the middle of its last ten years.

Over that time it ranged from 8.2× in Jun 2022 to 34.7× in Sep 2024.

The median for 8 large drugmakers of a similar size is 22.3×.

Price to free cash flow over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far15.6×13.8×17.7×
202513.7×10.9×18.4×
202418.3×17.1×34.7×
202319.9×8.3×21.1×
202212.3×8.2×12.4×
202111.1×9.4×19.8×
202019.7×14.2×22.0×
201918.1×14.1×18.1×
201814.9×13.2×16.3×
201715.1×14.0×15.5×
201614.5×12.1×15.1×
201513.4×11.7×15.6×
201411.8×9.6×12.4×
201311.8×11.6×13.5×
201211.1×7.8×12.2×
20118.0×5.9×17.0×
201015.4×14.6×22.3×

Against its peers

Companies in Drug Manufacturers - General nearest Pfizer's size, closest first, today.

CompanyPrice to free cash flow
PFEPfizer15.6×
GILDGilead Sciences14.9×
BMYBristol-Myers Squibb11.0×
AMGNAmgen23.3×
MRKMerck22.3×
ABBVAbbVie27.7×
JNJJohnson & Johnsonn/m
BIIBBiogen13.7×
LLYEli Lilly and65.9×
Peer median22.3×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Pfizer

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.